A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC. The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received. In this study participants will: * Take TRI-611 on a continued basis, provided it is well-tolerated, for as long as their disease is not progressing * Visit the clinic approximately seven times in the first 3 months and then just once at the start of each 28-day cycle thereafter * Keep a diary of each time they take the study medication
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznanie raka płuca bez drobnych komórek z mutacją ALK
- •Mierzalne zmiany nowotworowe
- •Prawidłowe funkcje szpiku kostnego i narządów
- •Wcześniejsze leczenie innymi lekami przeciw ALK (od 2 do 3 leków w zależności od grupy)
- •Wcześniejsze leczenie lekiem lorlatinib, ale nie jako pierwsza terapia
✗ Disqualifies
- •Nowotwór ma dodatkowe mutacje powodujące opór na leki przeciw ALK
- •Przerzuty do mózgu lub rdzenia kręgowego z postępującymi objawami neurologicznymi
- •Jednoczesne leczenie innymi lekami przeciwnowotworowymi
- •Alergia na TRI-611 lub jego składniki
- •Duża operacja chirurgiczna w ciągu 4 tygodni przed rozpoczęciem leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (11)
UCSF
San Francisco, United States
University of Colorado Cancer Center
Aurora, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Center
Boston, United States
Washington University Medical Center
St Louis, United States
Memorial Sloan-Kettering Cancer Center
New York, United States
Taylor Cancer Research Center
Maumee, United States
SCRI Oncology Partners
Nashville, United States
Oncology Consultants Research (P1 Trials)
Houston, United States
START Mountain Region
West Valley City, United States
NEXT Virginia
Fairfax, United States
Trial contact
TRIANA Clinical Trials
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.